US Patent

US10307417 — Oral formulations and lipophilic salts of methylnaltrexone

Formulation · Assigned to Wyeth LLC · Expires 2031-03-10 · 5y remaining

Vulnerability score 48/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects oral formulations and lipophilic salts of methylnaltrexone, specifically for oral administration.

USPTO Abstract

The present invention provides compositions comprising methylnaltrexone or a salt thereof, and compositions and formulations thereof, for oral administration.

Drugs covered by this patent

methylnaltrexone-bromide (METHYLNALTREXONE BROMIDE)

Patent Metadata

Patent number: US10307417
Jurisdiction: US
Classification: Formulation
Expires: 2031-03-10
Drug substance claim: No
Drug product claim: Yes
Assignee: Wyeth LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.